Q BioMed Inc (OTCQB:QBIO) has announced the appointment of Geoff Fatzinger as its head of regulatory affairs to focus on the company's global regulatory approval strategy to commercialize its lead cancer bone pain product - the non-opioid Strontium89.
"We are very happy to have Geoff join the team at Q BioMed. His deep global regulatory expertise and strategic leadership is critical as we reach some important milestones, including our effort to globally commercialize Strontium89," Q BioMed CEO Denis Corin said a statement.
Fatzinger, who brings with him 20 years of experience, will also contribute strategic regulatory insight and guidance for the portfolio of earlier stage assets.
He has a demonstrated record of regulatory and business accomplishments covering the United States, Europe, Middle East and Asia Pacific with in-depth experience in Japan, China, and Korea and has extensive experience in drug and device development, clinical trials, and approvals.
"Q BioMed is taking on projects which are providing medical benefit to those with byproducts of illnesses which often go overlooked or minimised. Medicine is not about the 'flavour of the month'," Fatzinger said. "I look forward to helping achieve these goals and bringing medicines to those who need it."
Q BioMed received FDA approval to manufacture and distribute Strontium89 in November last year.
The company completed an initial commercial production run and shipment in February and has begun distribution of the drug in the US, with distribution to EU and rest of the world expected later in the year.
Contact the author at [email protected]